Hot sale 849217-68-1 Cabozantinib CAS NO.849217-68-1

FOB Price: USD: 4.00-4.00 /Kilogram Get Latest Price
Min.Order: 1 Kilogram
Payment Terms: L/C,D/P,T/T
Available Specifications:
pharmaceutical grade(0-1000)Kilogram4/Kilogram0USD

Product Details

Keywords

Cabozantinib 849217-68-1
849217-68-1 Cabozantinib fast delivery
Hot sale 849217-68-1 Cabozantinib

Quick Details

ProName: Hot sale 849217-68-1 Cabozantinib
CasNo: 849217-68-1
Molecular Formula: C28H24FN3O5
Appearance: white powder
Application: API intermediate
DeliveryTime: from stock
PackAge: According to customer requirements
Port: shanghai or hangzhou or other china po...
ProductionCapacity: 1000 Metric Ton/Year
Purity: 98%min
Storage: dry and cool
Transportation: According to customer requirements
LimitNum: 1 Kilogram
Moisture Content: <0.1%
Impurity: less than 0.2%
heavy metals: less than 20ppm

Superiority

GIHI CHEMICALS exported this product to many countries and regions at best price. if you are looking for the material's manufacturer or supplier in china, GIHI CHEMICALS is your best choice. pls contact with us freely for getting detailed product specifications, product tech. date sheet, coa and msds, prices, delivery time and payment terms. as a leading manufacturer and supplier of chemicals in china, GIHI CHEMICALS not only supply popular chemicals, but also GIHI CHEMICALS's r&d center offer custom synthesis services. GIHI CHEMICALS can provide different quantities of custom synthesis chemicals in lab, plant and industrial.

Cabozantinib Basic information

Mechanism of action Pharmacokinetics Medicine interactions

Product Name:	Cabozantinib
Synonyms:	N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide;Cabozantinib;N-[4-[(6,7-Dimethoxy-4-quinolinyl)oxy]phenyl]-N'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide;XL184;Cabozantinib(XL184);XL-184 free base (Cabozantinib);BMS907351;N-(4-((6,7-DiMethoxyquino...
CAS:	849217-68-1
MF:	C28H24FN3O5
MW:	502
EINECS:	-0
Product Categories:	Inhibitors
Mol File:	849217-68-1.mol

Cabozantinib Chemical Properties

density

1.396

Safety Information

MSDS Information

Cabozantinib Usage And Synthesis

Anti-cancer drugs	Cabozantinib is a kind of a novel type of molecular targeted drugs developed by the United States Exelixis biopharmaceutical company. On November 29, 2012, the US Food and Drug Administration (FDA) approved the use of cabozantinib for the treatment of unresectable malignant local advanced or metastatic medullary thyroid carcinoma. In addition, Sorafenib, Vandernib and Levotinib have been approved by the Food and Drug Administration (FDA) for the treatment of advanced thyroid cancer.
Mechanism of action	In vitro biochemical and/or cytological analysis have shown that cabozantinib can inhibit the tyrosine kinase activity of RET, human hepatocyte growth factor receptor (MET), vascular endothelial growth factor receptor 1 (VEGFR-1, VEGFR-2, VEGFR-3, stem cell factor receptor (KIT), receptor kinase receptor (TRKB), FMS-like tyrosine kinase-3, FLT-3), AXL and human tyrosine kinase with immunoglobulinlike and EGF-like domains 2, TIE-2. All the above kinase receptors play an important role in the growth of normal cells and tumor cells. The abnormal expression of these receptors is critical in the development and progression of many kinds of tumors, including the inhibition of tumor cell apoptosis, participating into the tumor angiogenesis and invasion and other pathological processes. Cabozantinib exerts its antitumor effect by inhibiting the above kinase activity, killing tumor cells, reducing metastasis and inhibiting tumor angiogenesis.
Pharmacokinetics	The pharmacokinetic analysis showed that the half-life of this drug was about 55 h with the volume of distribution (V/F) being about 349L, and the clearance rate of CLL being about 4.4 L • h-1. Upon oral administration of this drug, the time for reaching plasma concentration peak time (tmax) is 2~5h. Compared with a single dose of oral administration of 140 mg • d ^ (-1) for 19 days, the exposure amount in vivo was increased to 4-5 times (based on the area under the drug-time curve) and can reach steady-state in 15th day. The drug has a high binding rate with plasma protein (≥ 99.7%). For healthy people subjecting to a single oral dose of 140 mg of this drug, a high-fat diet compared with the administration upon empty stomach, the maximal concentration (Cmax) and AUC are increased by 41% and 57%, respectively. In vitro studies have shown that cabozantinib is a CYP3A4 substrate. The CYP3A4 inhibitor will reduce the formation of its metabolite N-oxide (> 80%) while CYP2A9 inhibitor has a relatively small effect on the drug metabolism (<20%). CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C19, CYP2D6 and CYP2E1 have no effect on the drug metabolism. After a single dose of radiolabeled cabozantinib was administered to healthy subjects, 27% of the radioactivity appeared in the urine and 54% in the stool.
Side effects	In clinical trials, common adverse effects caused by cabozantinib include diarrhea, stomatitis, palmar-plantarrythrodysesthesia syndrome (PPES), and loss of weight, loss of appetite, nausea, fatigue, oral pain, taste disorders, high blood pressure, abdominal pain and constipation. The most common laboratory abnormalities (> 25%) were increased aspartate aminotransferase, alanine aminotransferase, lymphopenia, increased alkaline phosphatase level, hypocalcemia, neutropenia, thrombocytopenia, hypophosphatemia and hyperbilirubinemia. For patients receiving cabozantinib, 57% of patients have gotten increased level of thyroid stimulating hormone after initial dose, compared with patients receiving placebo, increased by 19%. Information regarding to the anticancer drug, mechanism of action, pharmacokinetics, side effects, and drug interactions of cabozantinib were compiled and edited by Yan Shi from Chemicalbook. (2015-10-23)
Medicine interactions	To healthy subjects, administration of strong CYP3A4 inhibitor, ketoconazole (400 mg • d-1, 27 days) can increase the single dose exposure amount (AUC0-inf) of the drug by 38%. Upon administration of this drug, it should be avoided of taking potent CYP3A4 drugs inhibitors such as ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin and voriconazole). To healthy subjects, administration of strong CYP3A4 inducing drugs, rifampicin (600mg • d-1, a total of 31 d) can reduce the single dose exposure amount (AUC0-inf) of the drug by 77%. It should be avoided of simultaneously administration CYP3A4 induced drugs (such as dexamethasone, Phenytoin, carbamazepine, rifampicin, rifabutin, rifapentine, phenobarbital and hypericum perforatum preparation). In the human liver microsomal (HLM) enzyme system, cabozantinib is the noncompetitive inhibitor of CYP2C8, CYP2C9 mixed inhibitor and the weak competitive inhibitor of CYP2C19 and CYP3A4. In the cultured human hepatocytes, carbotinib is a kind of CYP1A1 mRNA induction drug, but has no effect on CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19 or CYP3A4 mRNA or its isozyme system. In patients with solid tumors, the steady-state plasma concentration of carbotinib (≥100 mg • d-1 for a total of at least 21 days) showed no significant influence on plasma exposure amount (Cmax and AUC) of single doses of rosiglitazone (CYP2C8 substrate). Carbotinib is a P-glycoprotein transport inhibitory drug, but is not its substrate. Therefore, carbotinib may increase the plasma concentration of P-glycoprotein substrate.
Uses	XL184 (Cabozantinib, BMS-907351) is a potent multitargeted VEGFR2, Met, FLT3, Tie2, Kit and Ret inhibitor with IC50 of 0.035, 1.8, 14.4, 14.3 and 4.6 nM for VEGFR2, Met, FLT3, Tie2 and Kit, respectively.
Uses	Cabozantinib (XL184, BMS-907351) is a potent VEGFR2 inhibitor with IC50 of 0.035 nM and also inhibits c-Met, Ret, Kit, Flt-1/3/4, Tie2, and AXL with IC50 of 1.3 nM, 4 nM, 4.6 nM, 12 nM/11.3 nM/6 nM, 14.3 nM and 7 nM, respectively
Definition	ChEBI: A dicarboxylic acid diamide that is N-phenyl-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide in which the hydrogen at position 4 on the phenyl ring is substituted by a (6,7-dimethoxyquinolin-4-yl)oxy group. A multi-t rosine kinase inhibitor, used (as its malate salt) for the treatment of progressive, metastatic, medullary thyroid cancer.

Details

GIHI CHEMICALS, dedicated to the development, production and marketing of chemicals. we are a leading manufacturer and supplier of chemicals in china.

manufacturing base: the company has some manufacturing base in zhejiang, jiangsu and shandong provide. these bases focus on production and contract manufacturing.

strong quality control system: strength of our ethical commitment to quality control and quality assurance systems firmly based on iso standard. qa and qc used in the whole process of raw material control, process control and finished product quality inspection.

Quality Cooperation：GIHI CHEMICALS has established very good cooperation and business relations with hundreds of chinese qualified manufacturers by long time business intercourse.

rich experience in sales: our customers throughout the world, especially the world-renowned companies, such as bachem, basf, celanese, corden,dow,evonik, genzyme,henkel, merck,roche,sanofi,solvay.

Items	Specifications	Results
Appearance	Almost white powder	Conforms
Identification	H-NMR,HPLC	Conforms
Related substances	Any single impurity: ≤0.1% Total Impurities: ≤1.0%	0.05% 0.23%
Residual solvents	Petroleum ether: ≤0.03% Dimethyl sulfoxide: ≤ 0.5% Methylene chloride: ≤0.06% methanol: ≤0.3% Ethyl acetate: ≤0.5% Ethanol: ≤0.5%	0.02% 0.36% 0.01% 0.23% 0.25% 0.33%
Purity (HPLC)	≥99%	99.73%

Details

Items	Specifications	Results
Appearance	Almost white powder	Conforms
Identification	H-NMR,HPLC	Conforms
Related substances	Any single impurity: ≤0.1% Total Impurities: ≤1.0%	0.05% 0.23%
Residual solvents	Petroleum ether: ≤0.03% Dimethyl sulfoxide: ≤ 0.5% Methylene chloride: ≤0.06% methanol: ≤0.3% Ethyl acetate: ≤0.5% Ethanol: ≤0.5%	0.02% 0.36% 0.01% 0.23% 0.25% 0.33%
Purity (HPLC)	≥99%	99.73%

flexible payment terms: various payment terms such as l/c,d/p,d/a and t/t will be accepted. special notice: GIHI CHEMICALS never require customers to remit payment to a personal account. beware of being cheated